The financials
Celldex Therapeutics, Inc. by the numbers
Celldex Therapeutics, Inc. (CLDX) reported revenue of $22K in Q2 2026 (quarter ended June 30, 2026), down 97% from the same quarter a year earlier. That came with net loss of $74M. For the full year FY2025, revenue was $1.5M (−78% year on year) and net income −$259M. Its largest product in 2025-Q2 was Grant at $723K, 99% of the disclosed total, just ahead of Service at 1.0%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $22K | $730K | −97% |
| Operating income | −$81M | −$64M | n/a |
| Net income | −$74M | −$57M | n/a |
| Diluted EPS | −$0.94 | −$0.85 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Grant | $723K | 99% |
| Service | $7K | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $15.0K
Grant grew -98% year on year
Segment Latestyear on year
- Grant$15.0K$15.0Kyear on year -98%-98%
- Service--year on year --